# A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

> **NCT05036291** · PHASE1 · TERMINATED · sponsor: **Ningbo Newbay Technology Development Co., Ltd** · enrollment: 25 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** NB004 tablets

## Key facts

- **NCT ID:** NCT05036291
- **Lead sponsor:** Ningbo Newbay Technology Development Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-01
- **Primary completion:** 2025-09-24
- **Final completion:** 2025-10-10
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Development change
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036291, "A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05036291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*